Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

S. Gerritse; R. ter Heine; M. Labots; E. van den Hombergh; H. Dekker; D. Lehutová; M. Rudek; N. van Erp; H. Verheul

doi:10.1016/S0959-8049(20)31114-X

Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

S. Gerritse, R. ter Heine, M. Labots, E. van den Hombergh, H. Dekker, D. Lehutová, M. Rudek, N. van Erp, H. Verheul

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S19
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)31114-X
State	Published - Oct 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(20)31114-X

Cite this

Gerritse, S., ter Heine, R., Labots, M., van den Hombergh, E., Dekker, H., Lehutová, D., Rudek, M., van Erp, N., & Verheul, H. (2020). Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen. European Journal of Cancer, 138, S19. https://doi.org/10.1016/S0959-8049(20)31114-X

Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen. / Gerritse, S.; ter Heine, R.; Labots, M.; van den Hombergh, E.; Dekker, H.; Lehutová, D.; Rudek, M.; van Erp, N.; Verheul, H.

In: European Journal of Cancer, Vol. 138, 10.2020, p. S19.

Research output: Contribution to journal › Article › peer-review

Gerritse, S, ter Heine, R, Labots, M, van den Hombergh, E, Dekker, H, Lehutová, D, Rudek, M, van Erp, N & Verheul, H 2020, 'Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen', European Journal of Cancer, vol. 138, pp. S19. https://doi.org/10.1016/S0959-8049(20)31114-X

@article{e3d3d00ae80441e2aac3ad80ffc77db2,

title = "Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen",

author = "S. Gerritse and {ter Heine}, R. and M. Labots and {van den Hombergh}, E. and H. Dekker and D. Lehutov{\'a} and M. Rudek and {van Erp}, N. and H. Verheul",

note = "Funding Information: Other Substantive Relationships: Receive grants from: Novartis, Astellas, AstraZeneca, Bristol-Meyers Squibb, Gilead, Ipsen, Janssen, Pfizer, and Roche.",

year = "2020",

month = oct,

doi = "10.1016/S0959-8049(20)31114-X",

language = "English (US)",

volume = "138",

pages = "S19",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen

AU - Gerritse, S.

AU - ter Heine, R.

AU - Labots, M.

AU - van den Hombergh, E.

AU - Dekker, H.

AU - Lehutová, D.

AU - Rudek, M.

AU - van Erp, N.

AU - Verheul, H.

N1 - Funding Information: Other Substantive Relationships: Receive grants from: Novartis, Astellas, AstraZeneca, Bristol-Meyers Squibb, Gilead, Ipsen, Janssen, Pfizer, and Roche.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85093916257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093916257&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(20)31114-X

DO - 10.1016/S0959-8049(20)31114-X

M3 - Article

AN - SCOPUS:85093916257

VL - 138

SP - S19

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -